Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
TFV IVR
DRUG
2 trials
Sponsors
CONRAD
Conditions
Anti-Retroviral Agent
Contraception
HIV
Prevention
Phase 1
Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone
Completed
NCT02235662
CONRAD
Contraception, HIV
Start: 2014-10-31
End: 2015-12-31
Updated: 2016-01-11
Phase 2
Tenofovir/Levonorgestrel Intravaginal Ring and Tenofovir Intravaginal Ring
NCT03762382
CONRAD
Anti-Retroviral Agent, Contraception, HIV +1
Start: 2018-12-12
End: 2020-04-30
Target: 50
Updated: 2020-01-14
Related Papers
Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya
Frontiers in Reproductive Health
2023-06-13
6 citations
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study
PLoS ONE
2022-10-10
16 citations
Acceptability of an intravaginal ring for simultaneously preventing HIV infection and pregnancy: Qualitative findings of the Kisumu Combined Ring Study, 2019.
2022-09-23
6 citations
Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring
Frontiers in Cellular and Infection Microbiology
2022-03-08
19 citations
Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
PLoS ONE
2019-05-20
27 citations
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
2018-06-28
52 citations